8-K: BeyondSpring Reports Q1 2025 Financial Results and Highlights Plinabulin's Potential in Immunotherapy-Resistant Cancers

BeyondSpring announced its Q1 2025 financial results, highlighting promising clinical data for Plinabulin in combination therapies for NSCLC and Hodgkin lymphoma patients who have failed PD-1/L1 inhibitors, and progress in its SEED Therapeutics program.

Summary

• BeyondSpring Inc. announced its Q1 2025 financial results and provided a corporate update.
• Plinabulin has been administered to over 700 patients and shows a favorable safety profile.
• Early readouts in metastatic NSCLC and Hodgkin lymphoma patients who failed PD-1/L1 inhibitors showed durable responses.
• SEED Therapeutics' RBM39 molecular glue degrader achieved complete tumor regression in Ewing sarcoma models and is on track for an IND submission mid-2025.
• SEED's financials are now presented as discontinued operations under U.S. GAAP, as BeyondSpring sold a portion of its Series A-1 Preferred Shares of SEED in January 2025.
• BeyondSpring currently owns approximately 40% of the outstanding equity interest in SEED.
• R&D expense from continuing operations increased by 21% to $874,000 in Q1 2025.
• G&A expense from continuing operations increased by 30% to $1,736,000 in Q1 2025.
• Net loss from continuing operations increased by 24% to $2,584,000 in Q1 2025.
• Net income attributable to BeyondSpring Inc. was $4,477,000, compared to a net loss of $3,231,000 in the same period last year, primarily due to a gain on the sale of subsidiary interests.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical data and financial results, offset by increased expenses and ongoing losses from continuing operations. The positive momentum in clinical development and the gain on the sale of subsidiary interests contribute to a moderately positive sentiment.

Positives

• Plinabulin demonstrates a favorable safety profile after being administered to over 700 patients.
• Plinabulin shows promise in combination therapies for NSCLC and Hodgkin lymphoma patients who have failed PD-1/L1 inhibitors.
• SEED Therapeutics' RBM39 molecular glue degrader achieved complete tumor regression in Ewing sarcoma models.
• The company reported net income attributable to BeyondSpring Inc. of $4,477,000, a significant improvement from the net loss of $3,231,000 in the same period last year.

Negatives

• The net loss from continuing operations increased by 24% to $2,584,000 in Q1 2025.
• Both R&D and G&A expenses from continuing operations increased in Q1 2025.

Risks

• The company faces risks related to raising capital to finance future operations.
• Unexpected results of clinical trials could impact the company's prospects.
• Delays or denial in the regulatory approval process could hinder the commercialization of product candidates.
• Increased competition in the market could affect the company's ability to succeed.
• The company's ability to meet Nasdaq's continued listing requirements is a potential risk.

Future Outlook

The company expects to file an IND for its SEED Therapeutics' RBM39 molecular glue degrader in mid-2025 and is pursuing additional mechanism-targeted larger indications including liver cancer and KRAS-mutant tumors.

Management Comments

• Dr. Lan Huang stated that Plinabulin offers a potential option for the approximately 60 percent of cancer patients who progress on PD1/L1 inhibitors.
• Dr. Huang noted that early readouts in metastatic NSCLC and Hodgkin lymphoma who failed PD-1/L1 inhibitors showed durable responses that deserve further evaluation.
• Dr. Huang added that the RBM39 molecular glue degrader achieved complete tumor regression in mechanism-targeted Ewing sarcoma models and is on track for an IND submission midyear.

Industry Context

The announcement highlights the growing focus on developing therapies for cancers resistant to PD-1/L1 inhibitors, a significant unmet need in the oncology space. The development of molecular glue degraders represents an innovative approach to targeting traditionally undruggable targets.

Comparison to Industry Standards

• Plinabulin's potential to resensitize tumors to checkpoint inhibitors aligns with industry efforts to overcome resistance mechanisms, similar to approaches being explored by companies like Merck (Keytruda combinations) and Bristol-Myers Squibb (Opdivo combinations).
• The development of SEED Therapeutics' RBM39 degrader is part of a broader trend in targeted protein degradation, with companies like Arvinas and C4 Therapeutics also advancing degrader programs.
• The focus on Ewing sarcoma and KRAS-mutant tumors reflects a growing interest in addressing cancers with limited treatment options, similar to efforts by companies like Amgen (KRAS G12C inhibitor).

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical data and improved net income.
• Employees may be motivated by the progress in clinical development and the potential for new therapies.
• Patients may benefit from the development of new treatment options for cancers resistant to existing therapies.

Next Steps

• The company plans to submit an IND for SEED Therapeutics' RBM39 molecular glue degrader in mid-2025.
• Further evaluation of Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma is planned.
• The company will continue to pursue additional mechanism-targeted larger indications including liver cancer and KRAS-mutant tumors.

Key Dates

Keywords

Plinabulin, SEED Therapeutics, RBM39 degrader, NSCLC, Hodgkin lymphoma, Ewing sarcoma, Immunotherapy, Cancer therapeutics, Financial results, BeyondSpring